Tobalina and colleagues [41] analysed sequencing data available in the literature from tumour or circulating tumour DNA (ctDNA) of 327 patients with tumours harbouring mutations in BRCA1/2 (234 patients with ovarian cancer, 27 with breast cancer, 13 with pancreatic cancer, 11 with prostate cancer and 42 with a cancer of unknown origin) on progression after platinum or PARPi treatment. This evidence concerns the gene BRCA1 and Familial prostate cancer.